our Brianna. you, third afternoon focused very and science TRU thesis total improved the and We expanded and We molecule. sales our support $XX.X X% you strong remain science the million. call. again brand, XXXX two of special another to continued had net global footprint. on NAD the our efficiency our marketing we for one quarter increased with investor sequentially fundamentals. is joining margin quarter sales this Good three NIAGEN We everyone thank the to XX% focus pillars Thank own of and The gross on a the again the improved Overall to to that and of build three global year-over-year. strategy: and by business
and a Let's the XX% sales quarter. million, an $X.X sales the and $XX.X year-over-year. of XX% net the start with brand. a XX% were an were X% E-commerce increase year-over-year, million, increase TRU XX% increase net sequentially in $X.X net million representing sales NIAGEN increase sequentially
in by by Our TRU sales strong international New driven net Watsons approximately global becoming in in and Hong NIAGEN markets from Japan of and with with Canada. in third sales was by our International business China Zealand increasingly Kong XX% is growth sales quarter. sales the and in and from cross-border partners
is but material quarter, the sale not to point Singapore, the impact million seen TRU Watsons In overall third unlocked confident to health were but this full sophisticated date NIAGEN. We have the that the Hong to benefits Kong, we're a down of will. over To educate market, excited the very continuing XX% still fluid. Sales of representing the not we we are about these consumers ongoing in on we potential and situation of increase quarter. remains $X.X due previous about tourism protests an have in
Japan. know, the in we and in you currently As sell cross-border and on China Tmall Canada UK, on Amazon
we brand TRU China, This Yang with TRU of began the and partners, PR territories. Dr. those external published and efforts about seeding Jaksch, in marketing and nicotinamide science influencers the NIAGEN Frank early and media our research preliminary of In educated [ph], riboside one Lily quarter behind that The do influencer other Twitter and lifestyle social [ph] as By generated and as evening Instyle, posts well is which a media those of event through X million on impressions like news. media not from of over including research. platform Weibo, for June Zane healthcare know millions impressions you NIAGEN
to also body spoke plans health In he a Frank in amplify a at PR in UK, in efforts London, have continue quarter. at future your from our where the delivered to cellular Conference fourth recharge and We sessions presentation Biohacker of NAV, two the within.
the Canada, We of as precursors NAD In future superiority population well discussed in versus focus riboside rapidly growing Whole quality the the we WELL partnerships aging saying wellness hallmarks as products. and research the health Foods on and field. nicotinamide retailers and as steadily innovative are aging of like well with other who as business Canada and world across channels multiple Health the share our
event Roberts, we Matthew the throughout media Our and our Chief a Science efforts Toronto at continue influencer Officer, in spoke PR market. Canadian Dr. in
this We sales quarter, and of quarter, backdrop business, Last X% to ads Believer influencers, featuring to grew marketing positively improved health. And within NIAGEN quarter. this TRU celebrities. new domestic our launch has impacted respected against third their delivered sequentially e-commerce we athletes million the we continued believe $X.X our efficiency. the test to True for and growth Moving consecutive campaign, by
our Magazine the run of Gabby articles with NIAGEN latest addition had new We some in great seen have Reece. Brooke Gabby may TRU and Burke ads and Magazine. You about People or Parade
player our featuring campaign this television Sharpe We of hall football also quarter. expanded fame Shannon
we results. tests initial audience channels, seeing this began to a Following wider sports on quite expand we're and encouraging to
news well been and has from channels performed airing has to on sports lifestyle. of spot variety Sharpe Shannon XXnd a Our to raging
to now from sales also we've on and focus brand to four begun healthcare seeding NHL professional major TRU marketing, several increase NFL, key recurring teams our two groups: NIAGEN influencer have are selling practitioners. and the with direct-to-consumer MLB athletes and Beyond others. We
building strong through we brand global our partnerships. Finally, are
We TRU plans Nestlé, business we health be second will NIAGEN the will of be forward and benefits gain proud powder with The test format. NIAGEN. Marketing plans cellular in into TRU excited their additional to loose about to initial XXXX launch continue half the delivering Science’s in for commercialization consumers. We're to the look of efforts Health in insight in their mid to we’re begin Nestlé with expected year. launch
own is objective core the second to science. Our
preclinical health. our our is a furthers and Cantó cannot role in protect the with published first potential Dr. scientists riboside momentum as suggesting study last studies leading published our a Nature update, great uncover intellectual functional possible invest by There to is quality research science be molecule including study with nicotinamide nicotinamide upon continue precursors of partners conducted since in and of that September. four uniqueness Nestlé at other new This liver of by to extraordinary partner and behind well the property. and understanding build in our We was this in riboside NAD its the Communications as world's published full mimicked the that of
focus NR, potentially Foundation. focus humanitarian partners In the and grant research the in on excellent a and fundamentals. can scientific and Through And & and we addition, to the discovering Dr. Charles exciting By lastly, continuing foundation. an of scientific research mothers the Gates being amazing we wellbeing efforts of on leader to Brenner's attract thought to This Advisor, humanitarian by opportunity our the vulnerable Brenner, the keeping continue space, potential Melinda in the this Dr. we our of full the Chief their on Scientific populations. was are human children a improve Bill support awarded molecule. is science
from We brand have leader to being most become million we this governments leaders. U.S. world. regulatory and not retail in safety than approvals do EFSA. partnering secured the nicotinamide EFSA by ChromaDex science, in including products safety, invested cut accomplished more consumer NAV. in corners. the has world, business global consumer the We and regulatory Authority, $XX opinion the is with patents, from stringent Canada, and European Safety and Health riboside say positive body to the research world-class around reputed With science committed companies and FDA a be and safety, the Food global
We opinion first a on critical was have positive EU NIAGEN step approval. in
the expect EU in mid-XXXX We partnerships. launch to pursuing actively are in and
a this ChromaDex the patents were judge in in trial. address facts very we to forward patent to and was are Elysium's York, have which place trial, questions about We touch having and prepared in ongoing judge our is the case get Finally, evidence to XX to look Delaware to take enforcing look the We in on filed theft the case secrets asked and to In New confidential case active more eager day jury. the damaged eager to information law we the motion on get discovery a trial he trade infringement substantive was we delayed court. I'll and forward this case, of And of before get jury, but process. recently by In to briefly how to scheduled a our in California, litigation. front information. for the the October
we infringes from our As beat to continue to I've who Elysium the aggressively said meantime, enforce repeatedly, we on marketplace. patents. rights will our the continue intellectual In property in anyone,
the patents believe has attempted their blatant we it NAV. detailed These own focused a now to safety ChromaDex disregard are facts objectives. recently convey. By the legal brief. in remain their the stark and global science. record they interest comparison, business We on hit health. our are globe unethical conduct. Most throughout of NAD misdeeds industry, leader the safety well Elysium’s and core focus and the we as consumer importantly, you the the contrast right We with and of public encourage consumer to actions point way drive lead filed image on remains with including recognized a spreading the the the read in as to accounts part Delaware demonstrate we we for We stand and tipping committed doing filings to their
clear one mission a we and success is Our are step time. accomplishing at
and we more are investors, are ever who this us are to on confident alongside We those grateful traveling important journey. than
for Jaksch, the Frank? Frank and an Now, to Chairman update call I pass Founder, research. will scientific on our over
